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analysis from a societal perspective with a 3 month time horizon.
Direct medical costs (hospitalizations, drug therapies, specialist
visits, diagnostics, and laboratory exams) were quantiﬁed using
the National Health Service tariffs expressed in Euro 2005.
RESULTS: 220 patients were enrolled, 110 cases matched with
110 controls. The mean age was 66.0 years, 57.3% were male.
The mean total cost per patient-month was Euro 380.4 com-
pared to Euro 164.4 for cases and controls, respectively (P <
0.0001). On average, direct medical cost per patient-month was
estimated at Euro 368.6 in cases and Euro 149.8 in controls (P
< 0.0001). Hospitalizations accounted for the greatest propor-
tion of Health care costs in both groups, followed by drug ther-
apies (hospitalizations: 21.9% and 5.5%; drug therapies: 94.5%
and 68.2% in cases and controls, respectively). The working
ability reduction is higher in cases than in controls (P = 0.004).
CONCLUSION: The results of our analysis show that subjects
with cerebrovascular disease aged 40 to 79 years are more costly
than subjects without cerebrovascular diseases.
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OBJECTIVES: Clinical trials have shown that candesartan, an
angiotensin II receptor antagonist, improves survival and reduces
hospitalisation rates in patients with chronic heart failure (CHF)
and a reduced left ventricular ejection fraction (LVEF £ 40%).
This study assessed the cost-effectiveness of candesartan in the
management of CHF in Belgium. METHODS: Based on the 
outcomes (mortality, hospitalisation rate, cardiovascular events)
reported in the CHARM Programme (Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity), a
decision model was developed predicting the cost-effectiveness
of candesartan compared to placebo added to current standard
treatment (including diuretics, b-blockers, digoxin) of CHF. Two
populations with a LVEF £ 40% were analysed: those who were
intolerant of ACE-inhibitors (“alternative group”) and those
who were simultaneously treated with ACE-inhibitors (“added
group”). Direct costs from the health care payer’s perspective
(2004) were used. Effects were expressed as Life-Years gained
(LYG). The time horizon of the model was 3.14 years, based on
the follow up time in the CHARM programme, but also takes
into account that patients who survived the study period gain
life years and incur extra costs afterwards. An annual discount
of 3% was applied on costs and effects. The average cost per day
of candesartan (based on the average daily dose taken from the
CHARM-programme) was €1.06 in the “alternative” and €1.08
in the “added group”. RESULTS: The incremental cost-
effectiveness ratio was €1,214/LYG [95%CI €-8,365–€14,136]
in the “alternative” and €2,310/LYG [95%CI €425–€3,920] in
the “added” group. Sensitivity analysis showed the robustness of
the results. Monte Carlo analysis showed that, using a threshold
of €20,000/LYG, candesartan was cost-effective in 93.4% in the
“alternative” and in 99.8% in the “added” group. CONCLU-
SIONS: Administering candesartan to Belgian patients with a
LVEF £ 40% whether or not they are treated with ACE-
inhibitors seems cost-effective from the health care payer’s 
perspective.
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OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia with DDDR-MVP instead of
standard dual chamber pacing (DDDR) in France. DDDR-MVP
can reduce the amount of ventricular pacing. This may be advan-
tageous since previous studies have shown that more frequent
pacing of the ventricle increases the risk for heart failure and
atrial ﬁbrillation. METHODS: A discrete event simulation was
developed to estimate effects over ﬁve years. Identical patient
pairs were created, one received DDDR-MVP, the other DDDR.
During the simulation, each patient may develop post-operative
complications, pacemaker syndrome, heart failure, atrial ﬁbril-
lation (which may become chronic and require anticoagulants),
or have a stroke. The risk proﬁles depend on the patient’s char-
acteristics, device type and cumulative ventricular pacing. The
cumulative proportion of time receiving ventricular pacing is
based on data collected during a randomized, single-blind cross-
over trial of these devices. Risk functions for the association of
ventricular pacing with heart failure and atrial ﬁbrillation were
based on published data from the MOST trial. Life expectancy
is assumed the same with either device. Costs obtained from hos-
pitalization (re-operation, heart failure, stroke), and anticoagu-
lation, are reported in 2004 € and discounted at 3%. Each
analysis was based on 100 replications. Sensitivity analyses
covered all inputs and assumptions. RESULTS: Within 5 years,
29.1% of the patients in each cohort died. Discounted costs over
5 years were about €13,000 per patient; despite the higher initial
cost of DDDR-MVP mean additional cost was only €274 per
patient. DDDR-MVP is predicted to increase QALY by a mean
0.05 years, yielding a mean cost-effectiveness ratio of
€5,360/QALY. Sensitivity analyses showed the results were con-
sistent over a wide range of values. CONCLUSION: Based on
these 5-year estimates, the additional health beneﬁts of MVP
provide very attractive value for patients with sinoatrial-node
disease or intermittent atrioventricular block.
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OBJECTIVES: To examine the relationship between the Inﬂam-
matory Bowel Disease questionnaire (IBDQ) total score and
measures of utility (EQ-5D and the SF-6D scores), and to esti-
mate algorithms to map the two utility values from IBDQ scores.
METHODS: A large dataset, from ENACT I and II multina-
tional, randomized, placebo controlled clinical trials in moder-
ate to severe Crohn’s disease, provided contemporaneous patient
responses to all three questionnaires. Paired observations from
multiple time-points for patients from both trials were combined
in the analysis. The mean utility scores by IBDQ score deciles
were estimated. Spearman correlation coefﬁcients were calcu-
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lated for paired observations between IBDQ and EQ-5D (n =
3320) and IBDQ and SF-6D (n = 3230). Least square regression
models were investigated. RESULTS: The decile analysis demon-
strated a consistent positive relationship with both utility scores.
The correlations between the IBDQ and both the EQ-5D and SF-
6D were statistically highly signiﬁcant (p < 0.0001). The corre-
lation coefﬁcients for IBDQ with SF-6D and with EQ-5D were
0.85 and 0.76 respectively. A simple linear least square regres-
sion model of the relationship between EQ-5D and IBDQ
explained 46% of the variance. A visual inspection of the 
residuals plot for the IBDQ/SF-6D model suggested some non-
linearity and an improved non-linear model explained 72% of
the variance. The comparison of the two sets of values demon-
strated the commonly observed ceiling effect for the EQ-5D 
and ﬂoor effect for the SF-6D and provided added face validity
for the transformations. CONCLUSIONS: Given the strength,
consistency, and predictable characteristics of the relationships,
the algorithms appear to provide valuable and valid methods 
to estimate utilities from IBDQ scores in trials of Crohn’s 
disease patients that have collected IBDQ scores but not utilities.
The generalisability of this relationship to other groups of
patients, for which the IBDQ is appropriate, should be 
investigated.
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OBJECTIVES: To assess the relationship between (i) disease
severity and quality of life and (ii) disease severity and health
care resource use, in patients with Crohn’s disease. METHODS:
A prospective, cross sectional, pharmacoeconomics study was
conducted in ﬁve centres in Australia, with patients recruited by
specialist gastroenterologists. Each patient completed question-
naires comprising demographic, disease and health care utilisa-
tion questions, together with the disease-speciﬁc Inﬂammatory
Bowel Disease Questionnaire (IBDQ) and the Assessment of
Quality of Life (AQoL) multi-attribute utility instrument.
Disease severity was assessed by the gastroenterologist, using the
Crohn’s Disease Activity Index (CDAI). RESULTS: Of the 154
patients recruited, 11 were excluded due to incomplete datasets
or signiﬁcant co-morbidity. The 143 patients analysed had a
broad range of disease severity (CDAI 36-446), and included
23% with enterocutaneous ﬁstulae. Stepwise regression analyses
showed a negative relationship between disease severity and
quality of life—irrespective of whether the latter was measured
by the IBDQ (p < 0.0001) or the AQoL utility instrument (p <
0.0001). Age, gender and years since diagnosis did not signiﬁ-
cantly impact upon either of the quality of life outcomes. Health
care resource utilisation increased with increasing CDAI (p <
0.001), with hospital admissions being the largest component
cost. Even when patients with ﬁstulae were excluded, the mean
treatment cost for the most severe group (CDAI >= 220) was
AUD$7852 annually, excluding medications. Finally, despite
their young age (mean = 38yrs), 27% of patients received a Gov-
ernment beneﬁt; with the majority of these stating that this was
primarily due to their Crohn’s disease. CONCLUSIONS: More
severe Crohn’s disease is associated with poor quality of life for
patients and places considerable burden upon health care and
social welfare resources.
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OBJECTIVES: To compare 2 preference-based measures of
health, the EQ-5D and the SF-6D, in patients with pulmonary
arterial hypertension (PAH). METHODS: PAH patients (n =
278) were administered the EQ-5D and SF-36 questionnaires in
a sildenaﬁl clinical study. Comparisons of the utility indices of
the EQ-5D and the SF-36 (the SF-6D) were conducted using the
study baseline data. Comparisons were made using the total
group of patients, and a sub-group analysis by functional class
was also conducted. Functional class was assessed using the
WHO criteria for functional capacity and therapeutic class in
patients with PAH; there are 4 WHO functional classes (FC
I–IV), with higher classes associated with greater limitations in
physical activity. RESULTS: In the total group of patients, the
mean (SD) utility index scores of the EQ-5D and the SF-36 were
similar (0.632 [0.254] vs. 0.627 [0.116]), and the single-measure
intra-class correlation coefﬁcient between them was 0.51. Base-
line FC for treated patients was distributed as follows: FC I,
0.4%; FC II, 38.6%; FC III, 57.6%; FC IV, 3.2%. Given the low
proportions of subjects in FC I and FC IV, analyses were per-
formed on the combined groups of FC I/II and FC III/IV. The
mean (SD) utility index score of the EQ-5D exceeded the SF-6D
score in FC I/II patients (0.720 [0.205] vs. 0.672 [0.122]), but
was lower than the SF-6D score in FC III/IV patients (0.574
[0.266] vs. 0.597 [0.102]). CONCLUSIONS: The EQ-5D and
the SF-36 utility indices provide similar estimates for PAH
patients overall. However, the agreement between the instru-
ments is not consistent over the range of functional classes seen
in PAH patients.
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OBJECTIVES: Currently, there is only limited research into the
main determinants of QoL in patients with psoriatic arthritis
(PsA). With a number of novel treatments for PsA emerging, we
examined the associations between clinical outcomes and health
utilities for the purposes of economic evaluation. METHODS:
Patient-level data from a pivotal, Phase III, randomized con-
trolled trial of the fully human, anti-tumor necrosis factor mon-
oclonal antibody, adalimumab, vs. placebo in the treatment 
of PsA were analyzed. All potentially relevant outcomes were
included: patient-reported functional loss measured by the
Health Assessment Questionnaire Disability Index (HAQ-DI),
physician’s assessment of psoriasis severity from the Psoriasis
Area Severity Index (PASI), tender and swollen joint counts (TJC,
SJC), age, sex, and disease duration. All measurements were col-
lected for patients at baseline and Weeks 12 and 24. The health
utility measurement, the SF-6D was derived from responses to
the Short Form-36, a generic QoL questionnaire. Multiple linear
regressions using generalized estimating equations were
employed to identify signiﬁcant predictors of the SF-6D.
RESULTS: Mean baseline characteristics for 313 patients
